A five-year clinical audit in the haematology ward of a tertiary care hospital: establishing degree of correlation between bacteraemia and oro-pharyngeal screens in immunocompromised patients and role of prophylaxis  by Guleri, A. et al.
2S64 International Journal of Infectious Diseases I Volume 6, Supplement 2,2002 
cells/pL. Serum LDH and aminotransferase levels were 
normal. Treatment with AbelcetB (5 mg/kg daily) was 
initiated for bilateral Aspergillus furnigatus invasive 
pulmonary mycosis confirmed by CT scan and bronchial 
cultures. He showed significant improvement during 
2nd week and near-complete resolution of pulmonary 
densities on CT scan. Due to exacerbation of cutaneous 
and orointestinal tract GvHD, the patient was given 
therapy with equine anit-thymocyte globulin, tacrolimus, 
and high-dose methylprednisolone. The 3rd week was 
marked by recurrence of fever (>39”C), and several new 
upper lobe pulmonary lesions. Blood and bronchial 
samples were sterile. Abelcet@ dose was increased (7.5 
mg/kg daily), and oral itraconazole (400 mg liquid every 
8h) was initiated. On 24th day of hospitalization, he 
developed headache, 6th cranial nerve paralysis and 
unsteady wide-based gait. A superior vermian abnor- 
mality including intra-axial cerebellar lesion was noticed 
on magnetic resonance images of brain. Abelcet@ was 
increased to 10 mg/kg daily. He developed progressive 
weakness, obtundation, and died on hospital day 36. 
On postmortem examination a large necrotic abscess 
involving the cerebellar vermis that extended into 
posterior brain stem was seen. Branching, septate hyphal 
elements extending from cerebellar blood vessels were 
seen on histological examination, and S. apiospermum 
was isolated within 72 h. Antifungal susceptibility (MIC 
pg/ml) included: amphotericin B > 16.0; flucytosine 
>64.0; fluconazole 32.0; itraconazole 2.0; ketoconazole 
0.5; and voriconazole 0.5. Cerebellum tissue bioassay for 
free amphotericin B showed levels co.25 rJ,g/ml. 
Conclusions: Breakthrough invasive mycosis due to 
amphotericin B non-susceptible fungi is increasing. 
The newer broad-spectrum triazole-based agents with 
excellent central nervous penetration may significantly 
improve treatment options in patients at risk. 
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Blood stream infections (BSI) are a significant cause of 
morbidity and mortality among patients with cancer 
undergoing therapy. We evaluated all BSI which 
occurred in cancer patients at our institution during 
2000-01 in order to identify the causative pathogens. 
Nosocomial BSI was defined as symptoms and at 
least 2 positive blood cultures for coagulase-negative 
Staphylococcus (CONS) and other skin contaminants 
and one or more positive blood cultures for all other 
pathogens. 
A total of 399 episodes of BSI occurred in 273 patients. 
Of these patients hematological cancer (HC) was 
present in 104 and solid cancers (SC) in 169. Gram- 
positive pathogens were isolated in 221 (55%) of the 
BSI, gram-negatives in 161(40%) and candida spp. in 17 
(5%). Overall, the commonest pathogens isolated were 
S aureus 72 (18%) CONS 63 (16%) Klebsiella spp. 39 
(10%) E. coli 39 (10%) Enterococcus 33 (8%) 
Pseudomonas spp. 24 (6%) , viridans streptococci 22 (6%) 
Enterobacter spp. 18 (5%) Corynebacterium spp. 
11(3%), and S. pneumoniae 9 (2%). Among HC the 
predominant organisms were S aureus 20%) CONS 16%) 
Enterococcus 10%) Pseudomonas 9%, Klebsiella 7 % and 
S pneumoniae 3%. In SC the commonest organisms 
were S aureus 18%, CONS 16%, E.coli 14%, Klebsiella 
13 % , Enterococcus 7%) viridans streptococci 6 %, 
Candida 6%) and Pseudomonas 3%. Twenty-eight 
(27%) of the HC patients vs 29 (17%) of SC patients 
were neutropenic at the time of the BSI. In HC patients 
with neutropenia there were 41 episodes of BSI and the 
commonest organisms were Pseudomonas 17%, CONS 
17%, Enterococcus 12%, S. aureus 9%, Candida 7% and 
E. coli 7%. In contrast of the 34 episodes of BSI in SC 
patients with neutropenia the commonest organisms 
were E. coli 32%, Klebsiella 14%, S. aureus 12%, CONS 
9%, Pseudomonas 6%, and Acinetobacter 6%. 
Gram-positive pathogens were the commonest patho- 
gens isolated from BSI in cancer patients. However, 
the gram-negative pathogens such as E. coli, Klebsiella, 
and Pseudomonas are still significant causes of BSI 
especially among patients with neutropenia. Moreover, 
Pseudomonas still remains the most common pathogen 
isolated from BSI in HC patients with neutropenia. 
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Introduction: A clinical audit was carried out over 5 
years (1997-2001) in the immunocompromised patients 
including neutropenic patients and bone marrow 
(autograft) transplant recipients in hematology ward 
of Gartnaval General Hospital, Glasgow, a tertiary care 
center. 
Objective: It was aimed to establish the degree of 
correlation between bacterial isolates in oro-pharyngeal 
screen during bacteraemia episodes and role of anti- 
biotic prophylaxis. 
Methods: 2191 specimens from 255 patients with 
bacteraemia episodes were screened. 
Results: 29.4% (75/255) incidence of positive cor- 
relation, and 38.4% (981255) of negative correlation 
was observed. There was 32.1% (82/255) incidence of 
coagulase negative staphylococcus (CNS) bacteraemia. 
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Conclusion: CNS bacteraemia is most commonly 
associated with intravenous catheter infection, which 
was predominantly seen. Oro-pharyngeal colonization 
does account for a significant (29.4%) incidence of 
bacteraemia in the compromised host including neutro- 
penic and bone marrow transplant (autograft) recipients. 
Hence, prophylaxis with antibiotic is essential. 
A break up of the percentage of bacterial isolates to 
be presented. 
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Dendritic cells are rare cells that are principally involved 
in the presentation of antigen and stimulation of T 
lymphocytes. In chemotherapy treatment of neoplasms 
is bind with depreciated of immunological potential of 
patient. Development and function of dendritic cells 
may be inhibited by cytokines produced by cancer cells. 
The total number of 34 patients: 23 males and 11 
females, aged from 16 months to 17 years (median 11 
years) treated in the Department of Children Oncology 
and Hematology Medical University of Wroclaw, Poland 
(ALL-15 AML-9, NHL-2, HD-5, LCAL-3 children) 
were examined. Peripheral blood was collect at time of 
diagnosis and during chemotherapy and analyzed with 
used flow cytometric analysis. Concentration of a 
dendritic cells (CDllc+HLA DR+CD83+ CD86+) 
were examined. Phenotypic populations of elementary 
lymphocytes (CD3, CD4, CD8, CD16, CD19, CD56) 
with take into consideration markers of activation 
CD23, CD26, CD28, HLA-DR was analyzed. 
The dendritic cells were examined with use of specific 
markers for distinct blood dendritic cell populations: 
BDCA-1 (antigen presented on CD1lchish and CD123’“” 
dendritic cells with monocytoid morphology); BDCA-2 
(expression on CDllc- and CD123’ dendritic cells with 
plasmocytoid morphology); BDCA-3 (expression on 
CDlldim and CD123- dendritic cells with monocytoid 
morphology). 
The results of our study showed decreased level of 
blood the dendritic cells in our patients in comparison 
with control group of healthy children. 
Results of study were compared with reply of 
antineoplasm treatment. 
Work supported by grant 131 and 138. 
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Candida guilliermondii is rarely isolated from humans, 
but is considered a part of the emerging opportunistic 
fungi being recovered more frequently from severely 
immunocompromised patients. From January 1988 to 
December 1998 we identified 9 patients with C. guillier- 
mondii fungemia at our center. Most of the fungemias 
(5/9) occurred as a breakthrough infection on antifungal 
prophylaxis with agents such as fluconazole, Iiposomal 
amphotericin B, and itraconazole. Five of the 9 patients 
acquired the infection during their hospital stay 10-45 
days after admission and were considered as noso- 
comial, while the remaining 4 patients acquired the 
infection endogenously within O-4 days following admis- 
sion. Nosocomial fungemia was associated with hemato- 
logical malignancy most often occurring in leukemia 
patients in relapse, prior intensive chemotherapy, 
profound neutropenia, mucositis, steroid therapy, and 
concomitant multiple bacterial and fungal sepsis. Non- 
nosocomial fungemias were more often associated with 
solid tumors or hematological malignancy in remission, 
without steroids or mucositis, Both groups were treated 
with azoles and amphotericin compounds with variable 
outcomes. Four of the five patients in the nosocomial 
group died, while the only patient who survived had 
catheter-related fungemia. In contrast, all of the non- 
nosocomial cases survived the fungemia despite the fact 
that half of them (2/4) did not receive any treatment. 
Within the limitations of a small number, nosocomial 
C. guilliermondii fungemia occurring in the setting of 
hematologic malignancy and profound neutropenia 
is often a breakthrough infection with poor outcome 
despite aggressive antifungal therapy. 
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Between January 1993 and May 1998, we identified 
76 immunocompromised cancer patients (pts) with 
Candida glabrata fungemia. With the widespread use 
of fluconazole prophylaxis in 1992 at our center, the 
incidence of C. glabrata fungemia increased. Most im- 
munocompromised cancer pts with C. glabrata fungemia 
